FDA releases draft guidance for biosimilars

02/9/2012 | Wall Street Journal, The · Reuters · Bloomberg Businessweek

The FDA issued draft guidance for the approval of biosimilar drugs. The proposal would require companies to submit data from laboratory and clinical studies showing that biosimilars are "highly similar" to the original drugs. Dr. Rachel Sherman, the FDA's associate director for medical policy, called the process "an abbreviated pathway that will depend on existing data."

View Full Article in:

Wall Street Journal, The · Reuters · Bloomberg Businessweek

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Legal
Merck Sharp & Dohme
Whitehouse Station, NJ
Manager, Compliance
Fremont, CA
Director, Marketing
The Food and Drug Law Institute
Washington, DC
Vice President, Global Quality Collaboration, Standards & Harmonization
Canonsburg, PA
FDA/Life Sciences Associate Opening
K&L Gates LLP
Portland, OR